Summary The bioreductive cytotoxic agent SR 4233 (1,2,4-benzotriazine 3-amine 1,4-dioxide) has been shown to markedly potentiate the cell killing of mouse tumours when combined with fractionated radiation therapy. Differential metabolism under oxic compared to hypoxic conditions results in SR4233 exhibiting selective cytotoxicity to hypoxic cells. This is thought to result from the production of a cytotoxic free radical which is generated predominantly in the absence of oxygen. We have examined a way of enhancing the effectiveness of this antitumour agent in vivo by artificially increasing the hypoxic fraction of tumours by hypoxic breathing. Mice are placed in a chamber containing 10% Oxygen 90% Nitrogen for 1 h after each administration of SR 4233. Our results in the SCCVII tumour model indicate that this manoeuvre results in a 10-fold increase in antitumour effectiveness of SR 4233 when administered in a fractionated regime with radiotherapy (8 x 2.5 Gy and 0.08 mmol kg-'), but not when a single treatment regime (1 x 20 Gy and 0.3 mmol kg-') is used. Mathematical modelling of this effect is used to illustrate this phenomenon and can be used to predict the dependence of this type of therapy on the modification of tumour oxygenation.
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For several decades hypoxic cells residing within tumours have been regarded as a major obstacle to the effectiveness of radiation therapy (Bush et al., 1978; Dische et al., 1983; Henk, 1986) . These same cells have also been suggested to represent a population resistant to some chemotherapeutic agents (Kennedy et al., 1980; Tannock & Guttman, 1981; Teicher et al., 1990) . Efforts have therefore been made to 'overcome' the resistance of hypoxic cells to radiation using a variety of techniques including treatment with hyperbaric oxygen (Churchill-Davidson et al., 1957; Sealy, 1991; Watson et al., 1978) , high LET radiation's (Withers, 1973) and most recently, chemical hypoxic cell radiosensitisers (Adams et al., 1976; Coleman, 1988; Dische, 1991) . Hypoxic cell radiosensitisers have, so far, shown only marginal benefit in clinical settings primarily because of dose limiting toxicity (Coleman, 1988; Dische, 1991) . However, the quest for improved hypoxic cell radiosensitisers revealed a new class of compounds which exhibit selective toxicity towards hypoxic compared to oxygenated cells (Zeman et al., 1986). SR 4233 (1,2,4-benzotriazine 3-amine 1,4-dioxide) is a lead compound of this new class of antitumour agents and is presently undergoing Phase I clinical trials. The mechanism underlying the selective toxicity of SR 4233 toward hypoxic cells is believed to be due to the activation of SR 4233 by enzyme mediated single electron transfer to a cytotoxic free radical (Baker et al., 1988) . When oxygen is present this radical is 'back oxidised' to the parent species possibly allowing other reductive pathways, which do not result in free radical production and hence cytotoxicity, to predominate thus ameliorating the toxicity to oxygenated cells (Baker et al., 1988; Zeman et al., 1986) .
The differential cytotoxicity of SR 4233 to oxic and hypoxic cells can be exploited by using radiation to sterilise oxygenated cells and a bioreductive cytotoxin such as SR 4233 to kill the hypoxic cells of tumours. When these two modalities are combined into a fractionated treatment regime (a combination we have termed 'bioreductive radiotherapy') a potent synergistic antitumour effect is obtained (Brown & Lemmon, 1990) . The combination of hypoxic cell cytotoxins with radiation given in this form is predicted to be significantly better at controlling tumours than even the most potent hypoxic cell radiosensitiser or fully oxygenating all tumour cells (Brown & Koong, 1991 (Hirst & Wood, 1982) 
Treatment protocols
The single treatment comprised of animals receiving a dose of 20 Gy followed immediately by a dose of 0.3 mmol kg-' SR 4233 i.p. The mice were then placed in a clear plastic box (14 x 14 x 30 cm) which was gassed with 10% oxygen, 90% nitrogen at a flow rate of 5 1 min-'. The mice remained in this environment for 1 h after which they were returned to normal cages under ambient conditions. The fractionated treatments comprised 8 fractions of radiation, drug and low oxygen breathing. Mice were administered 0.08 mmol kg-' SR 4233 i.p. immediately after receiving 2.5 Gy radiation and preceding 1 h of breathing 10% oxygen 90% nitrogen. Treatments commenced at 8:30 am and 5:00 pm for four consecutive days. Control animals were untreated other than receiving saline injections instead of drug.
Excision assay
One day following the end of treatment the mice were killed and tumour response assessed. To do this the tumours wee aseptically removed and weighed, minced with curved scissors and added to 10 ml of Hank's buffered saline solution (Gibco, Grand Island, NY) containing 0.6 mg ml-' Pronase, 0.2 mg ml-' DNAse and 0.2 mg ml-' Collagenase. This mixture was agitated while being maintained at 37°C for 30 min after which the cells were filtered through a steel mesh (pore size approx 100 gm) and centrifuged at 450 x g for 10 min.
The cell pellet was resuspended in 10 ml of Waymouths medium (Gibco) containing 15% fetal calf serum (Irvine Scientific, Irvine, CA). Cells excluding trypan blue were counted and appropriate dilutions were made prior to plating. The plated cells were then incubated at 37°C for 13 days in humidified air containing 5% CO2.
Assessment of response
The action of SR 4233 in combination with radiation on tumours was assessed using the in vivo -in vitro excision assay. The number of trypan blue excluding cells extracted per tumour following excision and dissociation was compared to that from control animals in order to obtain an estimate of the fractional yield (FY) of cells from the tumours (i.e. total number of cells recovered from the treated tumour divided by the total number of cells recovered from the control tumours). The surviving fraction of the apparently viable cells extracted from the tumour; i.e. the fraction of cells which go on to form colonies, is calculated by dividing the plating efficiency of the cells from treated animals by the plating efficiency of the control population. By multiplying the surviving fraction by the FY the relative clonogenic cells per tumour is calculated. By examining the three parameters, not only the ultimate outcome of treatment can be observed (the relative clonogenic cells per tumour), but the contribution of the effects on the yield of cells from the tumour as well as the reduction in clonogenicity of those cells can be assessed.
Toxicity studies
To assess the effect of breathing 10% oxygen on the toxicity of SR 4233 non-tumour bearing mice were administered SR 4233 either as a single dose or fractionated doses in the same way as the experiments detailed previously. Three mice per dose group were used and the animals were closely monitored for toxicity for up to 30 days after administration. Animals were euthanised if found to be moribund or in distress. The results of experiments performed using a fractionated protocol are shown in Figure 2 . Eight doses of 2.5 Gy with or without SR 4233 (0.08 mmol kg-' per inj) were given over 4 days and followed the subsequent day by an excision assay. Panel a shows the relative number of clonogenic cells per tumour resulting from the different treatments. In the unirradiated groups only the tumours from mice treated with both SR 4233 and breathing 10% oxygen had values reduced from treatments without SR 4233. In the irradiated groups of animals which subsequently breathed air or 10% oxygen the number of clonogenic cells was reduced to about 2.5 x 10-3. In mice treated with SR 4233 the clonogenic cell survival was further reduced by about one logarithm to 2.5 x 10-4, and further reduced to about 2.5 x 10-5 when 10% oxygen was breathed in addition to the administration of SR4233. By examining panel b of Figure 2 it can be seen that the yield of cells was only sizably affected in unirradiated groups by the treatment with both SR 4233 and hypoxic breathing. The apparent decrease in the fractional yield of cells of the irradiated groups shown in panel b occurs because of the effect of the fractionated irradiation on tumour growth, because the tumour growth is retarded by the radiation treatment and therefore the fractional yields are lower than in the unirradiated groups. In the irradiated groups there is a decrease in fractional yield of tumours from mice treated with both SR 4233 and hypoxic breathing. Panel c shows the . The separation of the terminal slopes indicated the fraction of radiobiologically hypoxic cells as described by Moulder and Rockwell, 1984 and is equal to 6.5% (95% confidence limits of 2.82-14.79).
and fitting the data using the method described by Moulder & Rockwell (1984) the tumours were found to have a radiobiological hypoxic fraction of 6.5% (95% confidence limits 2.82-14.76).
Discussion
The cytotoxicity of SR4233 is oxygen dependent. In vitro studies show that SR4233 is between 40-150 times more toxic (defined by dose ratios to produce equivalent cytotoxicity) to cells in culture when exposed to the drug under hypoxic compared to oxygenated conditions (Zeman et al., 1986 Figure 1 . Experimentally, when SR 4233 is administered, as in Figure 1 , this survival is reduced 10-fold. In order to obtain this reduction in survival using the model shown in Figure 5 at least half the population of the tumour must be sensitive to the bioreductive agent, i.e. * must equal 0.5, and approximately 95% of the chemosensitive cells must be killed by the administration of the drug. The model then predicts that increasing the proportion of chemosensitive cells would increase the cell kill only marginally and this agrees with the experimental data shown in Figure 1 .
For fractionated irradiation with drug treatment the model predicts a different result. Figure 6 shows the experimental results shown in Figure 2 .
Although several assumptions are involved in the modelling of the effect of SR 4233 and hypoxic breathing on the sensitivity of tumours to bioreductive radiotherapy, the procedure provides a useful way of predicting the effect of various physiological and pharmacological manoeuvres. For example comparing Figures 5 and 6 it can be seen that if a high proportion of hypoxic cells are killed by the administration of SR 4233 then a much increased effect is achieved in fractionated compared to single treatment protocols. Also, increasing the proportion of hypoxic cells by hypoxic breathing has little effect on a single treatment, but can considerably enhance the antitumour effectiveness of fractionated protocols. 
Conclusions
The antitumour effectiveness of SR 4233 can be enhanced by increasing tumour hypoxia via exposure to a reduced oxygen environment. This manoeuvre causes some increase in systemic toxicity which may balance part of the improved antitumour effect, but these experiments clearly suggest that changing tumour oxygenation can modulate the therapeutic effect. Since the oxygenation of tumour is unstable and subject to fluctuations this way of improving the effectiveness of bioreductive agents may be a promising avenue of investigation. Modelling of the effectiveness of SR 4233 and hypoxic breathing is a useful means of understanding the most profitable ways of optimising its use.
